Regulus Therapeutics Inc RGLS shares are trading lower by $0.22 at $5.74 in Tuesday's session. After announcing positive top-line results for its Hepatitis C Virus C treatment, it appeared the issue was going into break-out mode.
However, off the open it found sellers in the same area it had in its last five sessions. After peaking between $6.02 and $6.25 in those sessions, it opened at its high print for the day, $6.10, and began to move sooth.
At this time, it's attempting to find support in the area of Monday's low ($5.64), with the current low standing at $5.62.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
